- Home
- PHUN vs BYSI Comparison
PHUN vs BYSI Comparison
Compare PHUN & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- BYSI
- Stock Information
- Founded
- PHUN 2009
- BYSI 2010
- Country
- PHUN United States
- BYSI United States
- Employees
- PHUN N/A
- BYSI N/A
- Industry
- PHUN EDP Services
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- BYSI Health Care
- Exchange
- PHUN Nasdaq
- BYSI Nasdaq
- Market Cap
- PHUN 58.3M
- BYSI 67.3M
- IPO Year
- PHUN N/A
- BYSI 2017
- Fundamental
- Price
- PHUN $2.98
- BYSI $1.73
- Analyst Decision
- PHUN Buy
- BYSI
- Analyst Count
- PHUN 2
- BYSI 0
- Target Price
- PHUN $7.50
- BYSI N/A
- AVG Volume (30 Days)
- PHUN 192.4K
- BYSI 20.0K
- Earning Date
- PHUN 05-12-2025
- BYSI 05-12-2025
- Dividend Yield
- PHUN N/A
- BYSI N/A
- EPS Growth
- PHUN N/A
- BYSI N/A
- EPS
- PHUN N/A
- BYSI N/A
- Revenue
- PHUN $2,956,000.00
- BYSI N/A
- Revenue This Year
- PHUN $10.47
- BYSI N/A
- Revenue Next Year
- PHUN $53.56
- BYSI N/A
- P/E Ratio
- PHUN N/A
- BYSI N/A
- Revenue Growth
- PHUN N/A
- BYSI N/A
- 52 Week Low
- PHUN $2.22
- BYSI $0.98
- 52 Week High
- PHUN $14.60
- BYSI $2.97
- Technical
- Relative Strength Index (RSI)
- PHUN 46.42
- BYSI 54.43
- Support Level
- PHUN $2.86
- BYSI $1.62
- Resistance Level
- PHUN $3.18
- BYSI $1.77
- Average True Range (ATR)
- PHUN 0.14
- BYSI 0.08
- MACD
- PHUN -0.02
- BYSI -0.00
- Stochastic Oscillator
- PHUN 16.29
- BYSI 70.53
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.